VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - May 28, 2007) - EnWave Corporation (TSX VENTURE:ENW)(FRANKFURT:E4U) (“EnWave” or “the Company”) is pleased to announce that it has entered into a Consulting Agreement with StarFish Medical (“StarFish”), a division of StarFish Product Engineering Inc. of Victoria, British Columbia, to guide the development of the next version of EnWave’s bioREV technology for the vaccine delivery sector. StarFish will initially provide expertise in the area of regulatory management to ensure that new designs for EnWave’s bioREV technology are FDA-compliant, and that the Company has abided by the necessary regulations in order to introduce this technology as a medical device into the U.S. market.
